Sickle Cell Disease Drug Pulled From Global Markets
Public Health & & Policy > Product Alert-- Benefits of voxelotor (Oxbryta) no longer surpass the threats, Pfizer states
by Mike Bassett, Staff Writer, MedPage Today September 26, 2024
Pfizer is pulling its sickle cell illness (SCD) treatment voxelotor (Oxbryta) from worldwide markets after information evaluation revealed an imbalance in deaths amongst clients taking the drug.
"The total advantage of the drug no longer exceeds the danger in the authorized sickle cell client population," the business revealed on Wednesday, including that the imbalance in deadly occasions and serious discomfort issues typical ...